Scinopharm Taiwan (TPE:1789) Retained Earnings: NT$383 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1789 Scinopharm Taiwan Ltd TPE:1789
76 GF Score
Price NT$19.00
GF Value NT$25.11
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Scinopharm Taiwan Retained Earnings?

Scinopharm Taiwan TPE:1789 -0.26% 76 Retained Earnings is NT$383 Mil as of Mar. 2026. GuruFocus rates TPE:1789 with a GF Score™ of 76/100 and a GF Value™ of NT$25.11 (Modestly Undervalued). The stock has 8 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Scinopharm Taiwan's retained earnings for the quarter that ended in Mar. 2026 was NT$383 Mil.

Scinopharm Taiwan's quarterly retained earnings increased from Sep. 2025 (NT$325 Mil) to Dec. 2025 (NT$366 Mil) and increased from Dec. 2025 (NT$366 Mil) to Mar. 2026 (NT$383 Mil).

Scinopharm Taiwan's annual retained earnings declined from Dec. 2023 (NT$495 Mil) to Dec. 2024 (NT$480 Mil) and declined from Dec. 2024 (NT$480 Mil) to Dec. 2025 (NT$366 Mil).


Scinopharm Taiwan  (TPE:1789) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Scinopharm Taiwan Retained Earnings Historical Data

* Premium members only.

The historical data trend for Scinopharm Taiwan's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scinopharm Taiwan Retained Earnings Chart

Scinopharm Taiwan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 657.98 565.44 494.88 480.23 366.46

Scinopharm Taiwan Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 526.25 309.48 324.93 366.46 382.98
TPE:1789
76GF Score
Scinopharm Taiwan Ltd TPE:1789
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scinopharm Taiwan Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of NT$383 Mil mean?
Scinopharm Taiwan (TPE:1789) has a Retained Earnings of NT$383 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Scinopharm Taiwan and its competitors.
Is Scinopharm Taiwan's Retained Earnings too high?
Scinopharm Taiwan's current Retained Earnings is NT$383 Mil. Overall, Scinopharm Taiwan has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Retained Earnings compare to ZTS?
Scinopharm Taiwan's Retained Earnings of NT$383 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Scinopharm Taiwan and its competitors. Scinopharm Taiwan's current Retained Earnings is NT$383 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$25.11, compared to a current price of NT$19.00 — trading 24.3% below its estimated fair value. The current Retained Earnings is NT$383 Mil. Scinopharm Taiwan's overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Retained Earnings is NT$383 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?

Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued. The current stock price of NT$19.00 is trading 24.3% below its estimated GF Value™ of NT$25.11. GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.

Key valuation signals for TPE:1789:

  • Retained Earnings: NT$383 Mil
  • GF Value™: NT$25.11 vs. price of NT$19.00 (24.3% below fair value)
  • GF Score™: 76/100 with 8 warning signs

No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Scinopharm Taiwan Business Description

Address Nan-Ke 8th Road, No. 1, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
76GF Score

Get the complete analysis for TPE:1789

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$19.00
Price
NT$25.11
GF Value